An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-small Cell Lung Cancer
Latest Information Update: 13 May 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYNOTE-025
- Sponsors Merck Sharp & Dohme Corp.
- 01 Mar 2019 Primary endpoint (Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Strongly PD-L1 Positive Participants) has not been met, according to the results published in the Cancer Science
- 01 Mar 2019 Results published in the Cancer Science
- 12 Apr 2017 Status changed from active, no longer recruiting to completed.